Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.

Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG.

J Neuroinflammation. 2017 Aug 18;14(1):164. doi: 10.1186/s12974-017-0935-1.

2.

LRRK2 levels in immune cells are increased in Parkinson's disease.

Cook DA, Kannarkat GT, Cintron AF, Butkovich LM, Fraser KB, Chang J, Grigoryan N, Factor SA, West AB, Boss JM, Tansey MG.

NPJ Parkinsons Dis. 2017 Mar 28;3:11. doi: 10.1038/s41531-017-0010-8. eCollection 2017.

3.

Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice.

MacPherson KP, Sompol P, Kannarkat GT, Chang J, Sniffen L, Wildner ME, Norris CM, Tansey MG.

Neurobiol Dis. 2017 Jun;102:81-95. doi: 10.1016/j.nbd.2017.02.010. Epub 2017 Feb 24.

4.

RGS10 deficiency ameliorates the severity of disease in experimental autoimmune encephalomyelitis.

Lee JK, Kannarkat GT, Chung J, Joon Lee H, Graham KL, Tansey MG.

J Neuroinflammation. 2016 Feb 1;13:24. doi: 10.1186/s12974-016-0491-0.

5.

The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

Moehle MS, Daher JP, Hull TD, Boddu R, Abdelmotilib HA, Mobley J, Kannarkat GT, Tansey MG, West AB.

Hum Mol Genet. 2015 Aug 1;24(15):4250-67. doi: 10.1093/hmg/ddv157. Epub 2015 Apr 29.

6.

Age-related changes in regulator of G-protein signaling (RGS)-10 expression in peripheral and central immune cells may influence the risk for age-related degeneration.

Kannarkat GT, Lee JK, Ramsey CP, Chung J, Chang J, Porter I, Oliver D, Shepherd K, Tansey MG.

Neurobiol Aging. 2015 May;36(5):1982-93. doi: 10.1016/j.neurobiolaging.2015.02.006. Epub 2015 Feb 13.

7.

Common Genetic Variant Association with Altered HLA Expression, Synergy with Pyrethroid Exposure, and Risk for Parkinson's Disease: An Observational and Case-Control Study.

Kannarkat GT, Cook DA, Lee JK, Chang J, Chung J, Sandy E, Paul KC, Ritz B, Bronstein J, Factor SA, Boss JM, Tansey MG.

NPJ Parkinsons Dis. 2015;1. pii: 15002. Epub 2015 Apr 22.

8.

Critical role of regulator G-protein signaling 10 (RGS10) in modulating macrophage M1/M2 activation.

Lee JK, Chung J, Kannarkat GT, Tansey MG.

PLoS One. 2013 Nov 21;8(11):e81785. doi: 10.1371/journal.pone.0081785. eCollection 2013.

9.

The role of innate and adaptive immunity in Parkinson's disease.

Kannarkat GT, Boss JM, Tansey MG.

J Parkinsons Dis. 2013;3(4):493-514. doi: 10.3233/JPD-130250. Review.

10.

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.

Rifkin RM, Greenspan A, Schwerkoske JF, Mandanas RA, Stephenson JJ, Kannarkat GT, Zhan F, Boehm KA, Asmar L, Beveridge R.

Invest New Drugs. 2012 Apr;30(2):714-22. doi: 10.1007/s10637-010-9556-6. Epub 2010 Oct 12.

PMID:
20938715
11.

Alcohol-induced alterations in hepatic microtubule dynamics can be explained by impaired histone deacetylase 6 function.

Shepard BD, Joseph RA, Kannarkat GT, Rutledge TM, Tuma DJ, Tuma PL.

Hepatology. 2008 Nov;48(5):1671-9. doi: 10.1002/hep.22481.

12.

Microtubule acetylation and stability may explain alcohol-induced alterations in hepatic protein trafficking.

Joseph RA, Shepard BD, Kannarkat GT, Rutledge TM, Tuma DJ, Tuma PL.

Hepatology. 2008 May;47(5):1745-53.

13.

Microtubules are more stable and more highly acetylated in ethanol-treated hepatic cells.

Kannarkat GT, Tuma DJ, Tuma PL.

J Hepatol. 2006 May;44(5):963-70. Epub 2005 Jul 27.

PMID:
16169115

Supplemental Content

Loading ...
Support Center